Drug Profile

ALG 010133

Alternative Names: ALG-010133; ALG-10133

Latest Information Update: 30 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aligos Therapeutics
Class Antivirals; Oligonucleotides
Mechanism of Action Hepatitis B surface antigen expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hepatitis B

Most Recent Events

22 Jun 2022 Updated adverse events and pharmacokinetics data from a phase I trial in Hepatitis B presented at the International Liver Congress 2022 (ILC-2022)
06 Jan 2022 Discontinued - Phase-I for Hepatitis B in Hong Kong, Moldova, New Zealand (SC) (Aligos Therapeutics pipeline, January 2022)
06 Jan 2022 Discontinued - Preclinical for Hepatitis B in USA (IV) due to lack of efficacy (Aligos Therapeutics pipeline, January 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com